PF-Atlas › Clinical Trials › NCT07002034
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
RE104 for Injection · Phase 2
Registry ID
NCT07002034
Phase
Phase 2
Status
Recruiting
Drug / intervention
RE104 for Injection
Sponsor
Reunion Neuroscience Inc
Start
2025-07-30
Enrollment
100
Locations
32
About this trial
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT07002034 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.